S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)

Boston Scientific (BSX) Stock Price, News & Analysis

$66.41
-0.58 (-0.87%)
(As of 09:45 AM ET)
Today's Range
$66.35
$66.83
50-Day Range
$55.62
$67.00
52-Week Range
$46.20
$67.32
Volume
314,444 shs
Average Volume
6.57 million shs
Market Capitalization
$99.62 billion
P/E Ratio
62.07
Dividend Yield
N/A
Price Target
$66.05

Boston Scientific MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1.4% Downside
$66.05 Price Target
Short Interest
Healthy
0.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.02
Upright™ Environmental Score
News Sentiment
0.56mentions of Boston Scientific in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$4.32 M Sold Last Quarter
Proj. Earnings Growth
12.89%
From $2.25 to $2.54 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

127th out of 958 stocks

Surgical & Medical Instruments Industry

17th out of 97 stocks


BSX stock logo

About Boston Scientific Stock (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Stock Price History

BSX Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Boston College at NC State odds, tips and betting trends
See More Headlines
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
2/29/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
10113710
Employees
48,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$66.05
High Stock Price Target
$80.00
Low Stock Price Target
$55.00
Potential Upside/Downside
-1.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
19 Analysts

Profitability

Net Income
$1.59 billion
Pretax Margin
13.94%

Debt

Sales & Book Value

Annual Sales
$14.24 billion
Cash Flow
$2.93 per share
Book Value
$13.02 per share

Miscellaneous

Outstanding Shares
1,500,000,000
Free Float
1,489,350,000
Market Cap
$100.50 billion
Optionable
Optionable
Beta
0.78

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Boston Scientific was last updated on Wednesday, February 21, 2024 at 2:44 PM.

Pros

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
  • The company offers products such as pacemakers, stents, defibrillators, and catheters, which are in high demand in the healthcare industry.
  • Boston Scientific has a strong track record of innovation and product development, staying ahead of competitors in the medical device market.
  • The company has a diverse product portfolio that caters to different medical needs, providing stability and growth opportunities.
  • Boston Scientific's recent financial performance has shown consistent revenue growth and profitability, indicating a strong position in the market.

Cons

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • While Boston Scientific has a strong product portfolio, it faces intense competition from other medical device companies, which could impact market share and pricing.
  • The healthcare industry is subject to regulatory changes and challenges, which may affect Boston Scientific's operations and profitability.
  • Investing in medical device companies like Boston Scientific carries inherent risks related to product recalls, lawsuits, and regulatory compliance issues.
  • The company's stock price may be volatile due to market conditions, industry trends, and macroeconomic factors, posing risks to investors.
  • Boston Scientific's financial performance is influenced by factors such as global economic conditions, healthcare spending, and technological advancements, which could impact investor returns.














BSX Stock Analysis - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 1 hold rating, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BSX shares.
View BSX analyst ratings
or view top-rated stocks.

What is Boston Scientific's stock price target for 2024?

19 equities research analysts have issued 12-month price targets for Boston Scientific's stock. Their BSX share price targets range from $55.00 to $80.00. On average, they predict the company's stock price to reach $66.05 in the next year. This suggests that the stock has a possible downside of 1.4%.
View analysts price targets for BSX
or view top-rated stocks among Wall Street analysts.

How have BSX shares performed in 2024?

Boston Scientific's stock was trading at $57.81 at the start of the year. Since then, BSX stock has increased by 15.9% and is now trading at $67.00.
View the best growth stocks for 2024 here
.

When is Boston Scientific's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our BSX earnings forecast
.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings results on Wednesday, January, 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.51 by $0.04. The medical equipment provider earned $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a trailing twelve-month return on equity of 15.99% and a net margin of 11.19%. During the same period in the prior year, the business posted $0.45 earnings per share.
Read the conference call transcript
.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY24 earnings guidance on Wednesday, January, 31st. The company provided EPS guidance of $2.23-2.27 for the period, compared to the consensus earnings per share estimate of $2.24. The company issued revenue guidance of ~$15.45-15.59 billion, compared to the consensus revenue estimate of $15.34 billion.

What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?

947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.56%), Massachusetts Financial Services Co. MA (3.90%), Primecap Management Co. CA (2.59%), Bollard Group LLC (1.53%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (1.44%) and Artisan Partners Limited Partnership (1.17%). Insiders that own company stock include Arthur C Butcher, Charles J Dockendorff, Daniel J Brennan, David A Pierce, David S Wichmann, Edward F Mackey, Edward J Ludwig, Eric Francis Yves Thepaut, Ian T Meredith, Jeffrey B Mirviss, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Maulik Nanavaty, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Vance R Brown, Wendy Carruthers and William F Bruss.
View institutional ownership trends
.

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Boston Scientific have any subsidiaries?
The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More
This page (NYSE:BSX) was last updated on 2/29/2024 by MarketBeat.com Staff